Alberto has 15 years’ experience in the pharmaceutical industry, having started his career as a sales person with Janssen in Spain. He joined the Mundipharma network of independent associated companies in 2003. Since that time, he has performed a number of key roles, including as Marketing Manager Analgesics at Mundipharma International Limited, a member of the network providing certain pre- and post-launch support to other members, primarily in the European region. He was also General Manager of Mundipharma Spain, where he led a corporate turnaround between 2008 and 2014, leading to the company achieving #1 Great Places to Work where it remains to date. Alberto was also previously the Managing Director of the network’s UK entity, Napp Pharmaceuticals. Prior to his current role, he was appointed Regional Director of Northern Europe for the Mundipharma network and in October 2016 he was given additional responsibility as European Director of Commercial Operations.
Alberto is now focused on driving forward the business through strategic priorities that include expanding and diversifying the network’s product portfolio ensuring the network is best placed to secure alliance opportunities at all stages of asset maturity across the commercial platforms of specialist driven primary care, speciality care and established brands.
He holds a PhD from Granada University and an Executive MBA from IE Business School, Spain.
Jim joined the Mundipharma network in 2010, initially as Head of Medical Affairs for oncology and then taking on responsibilities for new products. He moved into the Corporate and Business Development team in 2012 and is now responsible for business development, acquisitions, technology sourcing and strategic collaborations, along with alliance management.
He began his pharmaceutical career in 2002 at Fujisawa and then Astellas Pharma, where he held various positions in R&D, medical and marketing in a wide variety of therapeutic areas. Previously, Jim worked in academia for various leading institutions including the Institute of Child Health at The Hospital for Sick Children, Great Ormond Street, in haematology and oncology, and the Institute of Cancer Research, Royal Marsden Hospital.
Jim holds a degree in Medicinal Chemistry from University College London.
Chris brings an invaluable mixture of sales, business development, market access and commercialization expertise to his recent appointment as the European Director of Strategy and Commercial Excellence at Mundipharma. In this newly created role he is responsible for ensuring commercial excellence across our proven commercial platforms in specialist-driven primary care and specialty care, including our market leading biosimilars business in Europe.
Having started his pharmaceutical career in sales at Smiths Medical, Chris quickly progressed through positions of increasing responsibly with Cardinal Health, before joining Mundipharma as a Senior Business Development Manager in 2009. Since that time, he has excelled in various roles across the European network of independent associated companies including primary care sales in the UK, market access in the Netherlands and Director of the UK primary care business unit.
He holds a degree in International Business from Loughborough University Business School in the UK.
Bryan trained and practiced as a lawyer in London, Paris and Leeds, gaining experience working for a diverse range of international businesses, private clients and governments. Bryan joined Napp Pharmaceuticals in the UK in 1993 and has worked within the network ever since, managing legal, compliance and several other teams.
Bryan holds the position of European General Counsel. With an in-depth knowledge of the regulatory framework in which we operate, he strives to support our entrepreneurial culture while guiding the business through the requirements of an ever-changing regulatory and legal environment.
He holds a degree in modern history from the University of Oxford, UK and was awarded a distinction in his solicitor exams at the College of Law.
David began his career in biotechnology before moving to the pharmaceutical industry with Élan Pharmaceuticals, where he held key management positions in both the United States and Ireland. He joined Purdue Pharma L.P. in 2004, becoming Senior Vice President Technical Operations.
In 2015, David’s remit was extended when he became Technical Operations Director for the rest of the world. In this role, David oversees technical operations (Tech Ops) functions including manufacturing, supply chain, technical services and quality across the entire network of independent associated companies. He chairs the TOUR (Tech Ops US/ ROW) team, which oversees product supply activities and supply strategy across a range of global territories. David is also on the Board of the Rhodes independent associated companies based in RI, USA.
He holds a degree in molecular genetics from Trinity College, Dublin, Ireland.
Julie leads research and development for the Mundipharma network outside the US, guiding a portfolio of medicines through clinical trials to registration and reimbursement.
She joined Mundipharma from Purdue Pharma Canada where she was Vice President, Research and Development. Previously, Julie led the research and development of biologics and vaccines as General Manager of Human Health Therapeutics at the National Research Council of Canada (NRC), transforming it into one of NRC’s leading portfolios. Her move to the NRC followed almost 16 years at AstraZeneca in senior leadership roles building and leading cross-functional international teams. Earlier in her career, Julie spent nine years in clinical research in academia and the pharmaceutical industry.
Julie is also an adjunct Professor of Pharmacy at the Université de Montréal and sits on several scientific advisory boards. She holds a PhD from the University of Montreal, Canada, post-doctorates from Université Paris VI, France, and McGill University, Canada, and is fluent in both French and English.
Peter gained his first experience of working within the pharmaceutical industry with a five-year stint at Pharmaceutical Product Development (PPD), which began in 1994. Before that he had honed his analytical skills by working in the banking and finance industry for various fund managers, including MLC in Australia and Invesco in the UK. Having joined the Mundipharma network in 1999, Peter initially helped establish the Southern Europe business before progressing to the pan-European remit he holds today.
Peter is a qualified accountant (ACCA UK and CPA Australia) with a degree in business, majoring in economics, with a sub-major in finance from the University of Technology, Sydney, Australia.
David has amassed 20 years’ pharmaceutical industry experience, having joined Napp Pharmaceuticals in the UK in 1997 as Finance Manager and progressing to Chief Accountant. During his time at Napp, David broadened his professional experience by undertaking a variety of non-financial roles, including Regional Sales Manager, Marketing Associate, Head of Sales Training, Director of Operations and Director of Corporate Affairs. He returned to his financial roots when he became Financial Director of Napp in 2012. In 2015 he was appointed Chief Financial Officer for Europe.
David is a qualified chartered accountant, having begun his career at Ernst & Young. He also holds a degree in geography from the University of Cambridge, UK.
Neil started his legal career in 2002 when he joined London-based firm Bristows, specializing in intellectual property law. He moved in 2007 to Chicago, USA, obtaining his Juris Doctor from Northwestern University while working at the IP specialist firm, Banner & Witcoff, where he subsequently became a partner. In 2012, Neil returned to the UK to join Powell Gilbert LLP, continuing to specialize in patent litigation and advisory work in both high-tech and life sciences fields.
Neil joined the Mundipharma network in May 2015 as Director of European IP Strategy, moving quickly to Chief International IP Counsel.
Prior to studying law, Neil was awarded a PhD in biotechnology in 2001 from Cambridge University, UK, and he also holds a degree in molecular biology and biochemistry from Durham University, UK.
Philippe has amassed experience across a range of industry sectors. He was most recently with FTSE 100 global medical technology company Smith & Nephew plc, where he was Group CIO. Before that, Philippe was Group CIO at the specialist insurer Beazley Group plc. He began his career in the automotive sector, taking various positions in the Renault Group, including Regional CIO for South America, where he was based in Curitiba, Brazil. Philippe then moved to the UK to become Information Officer in charge of sales and marketing systems for General Motors Europe.
In his current role, Philippe is accountable for the IT services provided to the global network of independent associated companies.
He was educated in France and holds an engineering degree from École Centrale de Paris and a PhD in technology from Université Paris VI, France. Philippe is married with four children and is fluent in four languages.
Press return to search